Cadence Tempus Timing Solution is a static timing analysis and signoff platform that performs multi-mode multi-corner signoff, SI and variation-aware timing analysis, and distributed/parallel execution to accelerate timing closure and drive ECO fixes for large advanced-node digital IC designs.
Published Aug 24, 2026
| Starting Price | Not public (enterprise quote) | Not public (enterprise quote) | Open-source software; engineering and integration costs apply |
| Intended Fit | Cadence-centric implementation and signoff flows; large MMMC signoff with distributed scaling | Organizations standardized on Synopsys signoff; widely used as a reference signoff solution | Research, education, and internal checks; not typically used for leading-edge tapeout signoff |
| Key Strength | Integration with implementation/extraction tools in the Cadence flow; distributed STA capabilities | Broad adoption and established position as a reference signoff tool in many organizations | Transparency of code and low licensing cost; flexibility for experimentation |
| Key Weakness | Benefits may be strongest within a Cadence stack; pricing and adoption details are not public | Licensing cost and vendor lock-in considerations; transition costs for Cadence-centric teams | Limited foundry qualification and smaller ecosystem for production signoff |
—
PrimeTime and Tempus are the primary competitive axis in signoff STA. PrimeTime is widely used as an established reference; Cadence emphasizes Tempus’ scaling and integration within its implementation and signoff toolchain.
When comparing Tempus and alternatives, buyers should evaluate:
Public pricing for Tempus and PrimeTime is not available. Practical pricing comparisons are therefore based on procurement negotiations, existing tool footprints, and bundle arrangements.
Vendor announcements report adoption milestones and large-scale demonstrations. Product-specific market share data is not publicly available; procurement decisions should rely on peer references, foundry enablement status, and results from controlled proof-of-concept trials.